Coexistence of ankylosing spondylitis and Behçet's disease: Successful treatment with upadacitinib

Immun Inflamm Dis. 2024 Apr;12(4):e1242. doi: 10.1002/iid3.1242.

Abstract

Background: Ankylosing spondylitis (AS) and Behçet's disease (BD) are distinct inflammatory disorders, but their coexistence is a rare clinical entity. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors.

Case presentation: A 42-year-old woman presented with a decade-long history of lower back pain, nocturnal spinal discomfort, recurrent eye issues, oral and genital ulcers, hearing loss, pus formation in the left eye, and abdominal pain. Multidisciplinary consultations and diagnostic tests confirmed AS (HLA-B27 positivity and sacroiliitis) and BD (HLA-B51). Elevated acute-phase markers were observed.

Conclusion: This case fulfills diagnostic criteria for both AS and BD, emphasizing their coexistence. Notably, treatment with upadacitinib exhibited promising efficacy, underscoring its potential as a therapeutic option in patients with contraindications for conventional treatments. Our findings illuminate the intricate management of patients presenting with these two diverse systemic conditions and advocate for further exploration of JAK inhibitors in similar cases.

Keywords: Behçet's disease; ankylosing spondylitis; case report; sacroiliac joints; ulcers.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Behcet Syndrome* / complications
  • Behcet Syndrome* / diagnosis
  • Behcet Syndrome* / drug therapy
  • Female
  • HLA-B51 Antigen
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Spondylitis, Ankylosing* / complications
  • Spondylitis, Ankylosing* / diagnosis
  • Spondylitis, Ankylosing* / drug therapy

Substances

  • upadacitinib
  • Heterocyclic Compounds, 3-Ring
  • HLA-B51 Antigen